Vaxcyte (PCVX) Accumulated Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Accumulated Expenses data on file, last reported at $8.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $8.0 million, down 69.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (down 69.33% YoY), and the FY2025 annual result was $31.1 million, up 6.68% from the prior year.
• Accumulated Expenses fell to $8.0 million in Q1 2026 per PCVX's latest filing, from $31.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $54.2 million in Q1 2024 and troughed at $1.9 million in Q1 2023.
• A 5-year average of $17.7 million and a median of $13.7 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses tumbled 75.74% in 2023, then soared 2782.97% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $15.4 million in 2022, then dropped by 28.09% to $11.1 million in 2023, then surged by 163.41% to $29.1 million in 2024, then rose by 6.68% to $31.1 million in 2025, then sank by 74.3% to $8.0 million in 2026.
• Business Quant data shows PCVX's Accumulated Expenses at $8.0 million in Q1 2026, $31.1 million in Q4 2025, and $24.6 million in Q3 2025.